

Chemours Co  
Form 8-K  
July 01, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

July 1, 2016  
Date of Report (Date of Earliest Event Reported)

The Chemours Company  
(Exact Name of Registrant as Specified in Its Charter)

|   |                             |   |
|---|-----------------------------|---|
| Delaware  | 001-36794                   | 46-4845564                              |
| (State or Other Jurisdiction<br>Of Incorporation) | (Commission<br>File Number) | (I.R.S. Employer<br>Identification No.) |

1007 Market Street  
Wilmington, Delaware, 19899  
(Address of principal executive offices)

Registrant's telephone number, including area code: (302) 773-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 8.01 Other Events.

On July 1, 2016, certain officers and directors of The Chemours Company (“Chemours”) disclosed dispositions of Chemours securities through Form 4 filings with the Securities and Exchange Commission. The dispositions were related to investments under deferred compensation benefit plans of E. I. du Pont de Nemours and Company (“DuPont”) that the reporting persons participated in when they were employees or directors of DuPont. Following Chemours’ separation from DuPont on July 1, 2015, Chemours stock remained as an investment option under the DuPont plans until June 30, 2016. On June 30, 2016, the reporting persons’ investments were automatically allocated to other investment options according to the terms of the DuPont plans. The reporting persons did not sell shares of Chemours stock as part of these transactions.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**THE CHEMOURS COMPANY**

By: /s/ Mark E. Newman  
Mark E. Newman  
Senior Vice President and  
Chief Financial Officer  
Date: July 1, 2016